OncoMatch/Breast Cancer/BRCA2
Breast CancerBRCA2 Clinical Trials
Germline BRCA2 pathogenic variants are associated with HR-positive breast cancer more often than BRCA1 and confer sensitivity to PARP inhibition. Olaparib and talazoparib are FDA-approved for germline BRCA1/2-positive HER2-negative metastatic breast cancer. Active trials study PARP inhibitor combinations, neoadjuvant strategies, and activity in somatic BRCA2-altered tumors.
Top recruiting BRCA2 Breast Cancer trials
Ranked by phase and US site count. See all 15 trials matched to your profile →
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
Cambridge University Hospitals NHS Foundation Trust
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Massachusetts General Hospital
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
Rutgers, The State University of New Jersey
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
M.D. Anderson Cancer Center
Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
GBG Forschungs GmbH
Browse other molecular targets with active Breast Cancer trials.